ライフサイエンスコーパス: incidence rate

1 owed up after 12 months to calculate the HCV incidence rate.

2 n the contribution of sub-populations to the incidence rate.

3 es were the reasons for ICRS removal and the incidence rate.

4 timated with Cox regression and standardised incidence rates.

5 ion and urinary incontinence persist at high incidence rates.

6 We calculated the overall and quarterly HCC incidence rates.

7 an important influence on the variability of incidence rates.

8 ry-confirmed malaria episodes were reported (incidence rate 0.064 episodes per person-month at risk;

9 nts (71.8%) experienced drug-free remission (incidence rate = 0.28/person-year [PY], 95% confidence i

10 were observed over 28,949 eye-years at risk (incidence rate = 0.47% [0.40%-0.56%/eye-year]).

11 han those who passed on their first attempt (incidence rate .01, 95% CI 0.87-1.14).

12 87 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95

13 ia remained high in the study areas (overall incidence rates 12.5 [95% confidence interval (CI): 11.2

14 SGLT2i initiators compared with 129 events (incidence rate, 13.0 [95% CI, 10.9-15.3]) among sulfonyl

15 lure hospitalization, there were 141 events (incidence rate, 13.0 [95% CI, 11.0-15.2]) among SGLT2i i

16 4; 95% CI, 4.85-12.98), and all-cause death (incidence rate, 133.2 vs 86.8 per 1000 person-years; abs

17 ly higher risks of subsequent documented AF (incidence rate 136.4 vs 21.6 per 1000 person-years; abso

18 antly higher risk of ischemic stroke or TIA (incidence rate, 18.9 vs 10.0 per 1000 person-years; abso

19 e associated with an increased risk for DKA (incidence rate, 2.03 [CI, 1.83 to 2.25] versus 0.75 [CI,

20 ) among SGLT2i initiators versus 206 events (incidence rate, 20.8 [95% CI, 18.1-23.8]) among sulfonyl

21 ple progressed to dementia across all sites (incidence rate 24.9 cases per 1000 person-years).

22 urgeons who failed their first exam attempt [incidence rate 3.41, 95% confidence interval (CI) 2.27-4

23 g the null value, for myocardial infarction (incidence rate, 3.9 versus 1.8 per 1000 person-years; HR

24 patients with and without postoperative AF (incidence rate, 42.5 vs 25.0 per 1000 person-years; abso

25 llowing laparoscopic gastric bypass surgery (incidence rates 46.5, 95% CI 38.0-56.9/1000 person-years

26 gnificantly increased risk of heart failure (incidence rate, 5.4 versus 1.8 per 1000 person-years; HR

27 37 [95% CI, 0.88-2.13]) and ischemic stroke (incidence rate, 5.6 versus 3.2 per 1000 person-years; HR

28 posite end point was reached in 21 patients (incidence rate, 7.6% per year).

29 I, 1.14-3.03]) and cardiovascular mortality (incidence rate, 9.5 versus 4.7 per 1000 person-years; HR

30 nd in 78 patients in the antiplatelet group (incidence rates, 9.8 and 7.2 per 100 person-years, respe

31 Between 2012 and 2017, age-standardized incidence rate, age-standardized death rate (ASDR), and

32 a was significantly higher than the adjusted incidence rate among women with obesity (2.29 [95% CI, 2

33 umLabs(R) Data Warehouse, was used to assess incidence rates among individuals continuously enrolled

34 Accurate data on HCV prevalence and incidence rates among patients receiving opioid substitu

35 KS incidence rates among PLWH have decreased nationally bet

36 in cancer with one of the fastest increasing incidence rates among solid tumors.

37 ifactorial and most likely related to higher incidence rates among the elderly.

38 Incidence rates among women with diabetes (5.76 [95% CI,

39 oral Poisson models were used to fit the MiP incidence rate and assess health program effects.

40 sociation Women's World Cup to determine the incidence rate and subsequent medical assessment of head

41 ngham Heart Study cohorts, and estimated the incidence rates and hazard ratios of developing aortic a

42 er cancer cases in different scenarios using incidence rates and population from the Global Burden of

43 was to describe the all-cause mortality, TB incidence rates and their associated risk factors in a c

44 ultaneous monitoring of population immunity, incidence rates, and viral genetic and antigenic changes

45 In the United States, tuberculosis (TB) incidence rates are highest among adults aged >=65 years

46 women, corresponding to an age-standardized incidence rate (ASIR) of 438 and 330/100,000, respective

47 ed significantly increasing age-standardised incidence rates (ASIRs) for premenopausal breast cancer

48 attributable fractions and age-standardised incidence rates (ASIRs) of HIV-attributable cervical can

49 t 0.02% (95% CI: 0.01-0.02%) and reinfection incidence rate at 0.36 (95% CI: 0.28-0.47) per 10,000 pe

50 Poisson regression was used to compare incidence rates between HCV groups for end-stage liver d

51 sociated hospitalization in adults and found incidence rates comparable to pneumococcal disease where

52 m, 176/190 MSM (93%) were cured, and the HCV incidence rate declined from 0.53 per 100 patient-years

53 erature on epidemiological models, where the incidence rate dictating propagation of infections is ta

54 However, diagnosed incidence rates did not rise uniformly across sociodemog

55 n users and nonusers, respectively (weighted incidence rate difference [IRD]/1000 person-years, -19.5

56 The cumulative incidence rate difference between groups is -0.05 (95% c

57 Although age-standardized incidence rate for cirrhosis increased from 66.0 to 66.3

58 The incremental increase in the incidence rate for migraine with aura ranged from 1.01 a

59 The incidence rate for women with migraine with aura was sig

60 Primary safety outcomes included cumulative incidence rates for (serious) adverse events.

61 ce rate ratios comparing post-IRS to pre-IRS incidence rates for age groups 0-3, 3-5, and 5-11 were 0

62 Incidence rates for anterior uveitis, the most common op

63 We examined incidence rates for cirrhosis and hepatocellular carcino

64 Incidence rates for episcleritis and scleritis were 15.3

65 Incidence rates for lower extremity deep vein thrombosis

66 ere used to calculate multivariable-adjusted incidence rates for major CVD events by risk factor stat

67 s (SEER) program data were used to calculate incidence rates for various cancer types in 607 U.S. cou

68 rimary time-independent models using average incidence rates from 1992-2016 and average PM2.5 from 19

69 n addition, time-varying models using annual incidence rates from 2002-2011 and lagged moving average

70 However, the incidence rate has doubled in the elderly.

71 Herpes zoster incidence rates have continued to increase in age groups

72 Since 2007, annual HZ incidence rates have decreased in individuals <=20 and >

73 We estimated incidence rates, hazard ratios using adjusted cox-regres

74 The HCV reinfection incidence rate in MSM was also compared to the incidence

75 The incidence rate in patients >80 years of age doubled from

76 2.4 [95% confidence interval, 1.9-3.0]), the incidence rate in patients with CD4 counts >500 cells/mu

77 cidence rate in MSM was also compared to the incidence rate in the interferon era (using data from th

78 TB incidence rates in 2035 would be 43% (95% uncertainty in

79 the most recent CD4+ T-cell count, pregnancy incidence rates in HIV-positive women receiving ART were

80 Chlamydia and gonorrhea incidence rates in persons with HIV were 1,432 and 1,687

81 Mortality and TB incidence rates in the 2-year period after TB was initia

82 t and inpatient community-acquired norovirus incidence rates in the first and third years of surveill

83 h one of the highest recorded thyroid cancer incidence rates in the world.

84 Rapidly increasing incidence rates in younger people could result from gene

85 Incidence rate, infection characteristics, clinical asso

86 7,159 person-years of follow-up (PYFU): 540 (incidence rate [IR] 22.5/1000 PYFU [95% CI 20.7-24.5]) o

87 ancers among treated patients: rituximab 33 (incidence rate [IR] per 10,000 person-years = 34.4, 95%

88 io [SIR] vs general population, and absolute incidence rate [IR]), prevalence of anal squamous abnorm

89 Early-onset colorectal cancer (EOCRC) incidence rates (IRs) are rising, according to previous

90 Using Poisson regression, we calculated incidence rates (IRs) of GWs per 100 000 person-years an

91 We calculated incidence rates (IRs) of hospital-attended HZ in Ontario

92 ), Montreal Cognitive Assessment (MoCA), and incidence rates (IRs) of nonvertebral fractures and infe

93 Ten HFCAs with incidence rates marginally above this threshold (pMDA gr

94 BIA-ALCL incidence and incidence rates may be higher than previous epidemiologi

95 This corresponds to an incidence rate of 0.04 cases per person-year.

96 nmasking and 8 paradoxical), with an overall incidence rate of 0.74 cases per 1000 HIV-infected perso

97 176 infections among PWID over 5 years or an incidence rate of 12.1/100 person-years.

98 , 7,614 new asthma cases occurred, giving an incidence rate of 5.7 (95% CI = 5.5-5.8) per 1,000 perso

99 [SD 9.1] years) during the follow-up with an incidence rate of 5.9 per 100 000 observation years.

100 on-years), 25,288 women developed asthma, an incidence rate of 7.0 (95% CI, 6.9-7.1) per 1000 person-

101 ARBs vs other antihypertensive drugs and the incidence rate of a COVID-19 diagnosis in a cohort of pa

102 The incidence rate of AEs was 42.65 per 100 person-years and

103 In preterm-born children, the cumulative incidence rate of any mental and behavioral disorder was

104 Using WHO categories, the crude incidence rate of any visual loss based on PVA and BCVA

105 The 5-year incidence rate of aSBO was higher after open surgery com

106 The incidence and incidence rate of BIA-ALCL were estimated per patient an

107 s study sought to estimate the incidence and incidence rate of breast implant-associated anaplastic l

108 There was no difference in the incidence rate of complications including pancreatitis,

109 ith migraine with aura had a higher adjusted incidence rate of CVD compared with women with migraine

110 I, 14.3-14.5) in the general population; the incidence rate of death from COVID-19 was 1.3 (95% CI, 0

111 Compared with low coverage practices, incidence rate of detection in medium and high coverage

112 ures were the incidence of ocular remission, incidence rate of disease relapse after remission, and r

113 We assessed risk and incidence rate of documented SARS-CoV-2 reinfection in a

114 We estimate that the incidence rate of emergency department-attending sepsis

115 aseline CNV total area and leakage area, the incidence rate of first sustained gain of 15 letters or

116 ], 48.2 letters at baseline) showed a higher incidence rate of first sustained gain of 15 letters or

117 Also, there were no differences in the incidence rate of flare events with the switch (IRR: 1.0

118 The quarterly incidence rate of HCC remained stable between 1.00 and 1

119 The incidence rate of hospitalization for COVID-19 was 11.7

120 uited ICUs, the cumulative incidence and the incidence rate of ICU-acquired Pa infections were 3.38%

121 The incidence rate of ischemic stroke or systemic embolism w

122 We, therefore, aimed to assess the incidence rate of LVNC-related cardiovascular events.

123 The adjusted incidence rate of major CVD per 1000 person-years was 3.

124 The incidence rate of NRH was within the background incidenc

125 The annual incidence rate of pcsAION within 2 months of surgery (8.

126 The overall incidence rate of PHN was 57.5 (95% CI: 56.0, 59.0) case

127 The incidence rate of psychotic experiences increased betwee

128 Risk and incidence rate of reinfection were estimated.

129 The primary outcome is the incidence rate of RSV-associated hospitalization in the

130 as not significantly greater than the annual incidence rate of sAION (6.9 per 100,000; P = .78).

131 The incidence rate of small bowel obstruction during pregnan

132 The incidence rate of submicroscopic P. falciparum infection

133 The incidence rate of symptomatic RSV was 248.1 cases per 10

134 tient-days, P = .02) but had a similar crude incidence rate of the negative control outcome (4.5 vs 3

135 The CHG group (n = 485) had a crude incidence rate of the primary outcome that was 60% lower

136 om 1990 to 2013, the global age-standardized incidence rate of thyroid cancer increased by 20%.

137 The incidence rate of VF was 7.0, 2.0, and 0.5 per 100 perso

138 The incidence rate of VTE was 16%, with 69% of cases occurri

139 veloped in 31 eyes (16%) with 5- and 10-year incidence rates of 12% and 28%, respectively.

140 The primary outcome was incidence rates of adverse events (AEs) and serious AEs.

141 The incidence rates of all-cause mortality, stroke and syste

142 Age- and sex-standardized incidence rates of AMI declined from 322.4 (95% CI, 311.

143 The incidence rates of aortic aneurysm and dissections appro

144 The 5-year cumulative incidence rates of BCRL were 30.1%, 24.9%, 10.7%, and 8.

145 Incidence rates of cardiomyopathies, which are a common

146 The increased incidence rates of cirrhosis reported in Halland are mul

147 At 10 years, the cumulative incidence rates of CRC for individuals with no polyp, pr

148 Incidence rates of diarrhea for 5-month periods before a

149 es with occult CNV at baseline showed higher incidence rates of first sustained absence of retinal fl

150 k factors including metabolic disorders, the incidence rates of HCC are still rising.

151 Incidence rates of hospitalization and death per 10,000

152 vailable, there have been few studies on the incidence rates of HZ and post-herpetic neuralgia (PHN)

153 The incidence rates of IASCC were 21.9 (95% confidence inter

154 Incidence rates of IPD and CAP in PLWH were 111 and 1529

155 In almost all countries, incidence rates of liver cancer (LC) are 100%-200% highe

156 High incidence rates of liver injury among cotreated human im

157 Pooled reported annualized incidence rates of MACE in those without baseline CVD we

158 ter adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups.

159 aortic aneurysm and dissections approach the incidence rates of other common cardiovascular condition

160 We analyzed the HCV reinfection incidence rates of participants in the German hepatitis

161 The incidence rates of pcsAION and sAION were compared using

162 wave, crude and age-standardized cumulative incidence rates of SARS-CoV-2 infection were 5.3% versus

163 e implementation of HIV PrEP and the growing incidence rates of sexually transmitted infections (STIs

164 The incidence rates of spontaneous myocardial infarction or

165 Incidence rates of this disease have increased in many c

166 conducted a regression analysis on 2003-2016 incidence rates of thyroid cancer, adjusting for distanc

167 The incidence rate per 1,000 person-years of new-onset, admi

168 7 composite cardiovascular end point events (incidence rate per 1000 person-years, 9.9 [95% CI, 8.1-1

169 The corresponding incidence rates per 10 000 person-years of follow-up in

170 Age- and sex-standardized incidence rates per 100 000 person-years were calculated

171 uding indefinite for dysplasia) at baseline, incidence rates per 100 person-years were 1.09 (95% CI,

172 o estimate survival probabilities and report incidence rates per 100 person-years.

173 Diabetes incidence rates per 1000 person-years were 20.6 (95% con

174 ignificantly higher 5-year exposure adjusted incidence rates (per 100 patient-years) of SVD (1.61 +/-

175 Incidence rates (per 1000 person-years) of all-cause mor

176 Despite increasing incidence rates, prognosis of invasive cutaneous squamou

177 The age- and sex-adjusted incidence rates ranged from 6.6 (other Hispanic/mixed ba

178 Model estimates showed 69% (adjusted incidence rate ratio (IRR) 0.31, 95%CI, 0.20-0.67) and 5

179 e use of glitazones and Parkinson's disease [incidence rate ratio (IRR) 1.17; 95% confidence interval

180 more network members than male participants: incidence rate ratio (IRR) 1.95, 95% confidence interval

181 ased diarrhea when it followed a dry period [incidence rate ratio (IRR) = 1.26; 95% confidence interv

182 The incidence rate ratio (IRR) for hospital re-re-admission

183 Men showed an HZO incidence rate ratio (IRR) of 0.74 compared with women.

184 Poisson regression was used to estimate the incidence rate ratio (IRR) of HIV acquisition in newly c

185 regression analysis was used to estimate the incidence rate ratio (IRR) of quiescence between the 2 t

186 the upper bound of the 95.003% CI of the HIV incidence rate ratio (IRR) was less than the prespecifie

187 t associated with leprosy incidence overall (incidence rate ratio (IRR)Poisson = 0.97, 95% CI: 0.90,

188 Adjusted incidence rate ratio (IRRs) were estimated using Poisson

189 the number of organs transplanted per donor (incidence rate ratio 0.43, 95% confidence interval [CI]

190 rfMDA than in those receiving RACD (adjusted incidence rate ratio 0.52 [95% CI 0.16-0.88], p=0.009),

191 ars in 2012 to 0.5/100 person-years in 2019 (incidence rate ratio 0.75; CI:0.68-0.83;p<0.001).

192 received azithromycin was lower for malaria (incidence rate ratio 0.78, 95% CI 0.66-0.92; p=0.0029),

193 t not readmission (OR 1.1, P = 0.48) or LOS (incidence rate ratio 1.0, P = 0.14).

194 amin D(3) group and 94 in the placebo group (incidence rate ratio 1.06, 95% CI 0.80-1.41; p=0.66).

195 nce between groups in fall rates (unadjusted incidence rate ratio 1.19, 95% CI 0.78 to 1.83; p = 0.43

196 increase in the number of outpatient visits (incidence rate ratio 1.29, 95% CI 1.27-1.31), and number

197 s 0.15 (0.46) in the control group; adjusted incidence rate ratio 1.55 (95% CI 1.15 to 2.09).

198 with nulliparous, in an age-adjusted model (incidence rate ratio 7.04, 95% CI 5.87-8.43).

199 t decrease in 30-day mortality was detected (incidence rate ratio = 0.06, 95% confidence interval: 0.

200 rate of unplanned cancer-related admissions (incidence rate ratio = 0.83, 0.73-0.95; p = 0.007).

201 h 4.4% decline in intensity of re-infection (incidence rate ratio = 0.96, 95% CI: 0.93-0.98, p=0.004)

202 fference in the need for pretransplant ECMO (incidence rate ratio = 1.16, P = .12).

203 grade versus no lesion at baseline (adjusted incidence rate ratio = 3.0; 95% confidence interval, 1.0

204 ric Cerebral Performance Category score > 1, incidence rate ratio = 3.50, 95% confidence interval [CI

205 HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and

206 seen in 12- to 17-year-old females (adjusted incidence rate ratio [aIRR] 1.12, 95% confidence interva

207 number of P. falciparum infections (adjusted incidence rate ratio [aIRR] =1.3; p=0.098).

208 ssociated with unfavorable outcome (adjusted incidence rate ratio [aIRR], 1.21 [95% confidence interv

209 s 18-34 years old with KDPI >= 35% (adjusted incidence rate ratio [aIRR]: (0.18) 0.21(0.25) , P < .00

210 ntly higher for children of migrant mothers (incidence rate ratio [IRR] 1.19 [95% CI 1.01 to 1.40], p

211 The risk of dry eye syndrome (adjusted incidence rate ratio [IRR] 4.45, P < 0.001), cataracts (

212 ervention and control areas in all forms TB (incidence rate ratio [IRR] = 1.136 [1.072, 1.204]; p <=

213 The largest effects occurred with CHF (incidence rate ratio [IRR] range, 4.84-13.4 across age s

214 ars was significantly lower for serotypes 1 (incidence rate ratio [IRR], 0.03 [95% CI, 0-.19]) and 7F

215 knowledge gap incidence from 0.085 to 0.065 (incidence rate ratio [IRR], 0.737 [95% CI, 0.600 to 0.87

216 ed with a lower rate of new cases at 5 days (incidence rate ratio [IRR], 0.85 [0.76, 0.96]; P = .009)

217 adherence associated with the intervention (incidence rate ratio [IRR], 1.73 [95% confidence interva

218 a higher risk of cervical artery dissection (incidence rate ratio [IRR], 2.2; 95% CI, 1.3-3.5), with

219 in patients with CD4 counts <500 cells/muL (incidence rate ratio [IRR], 6.1 [95% confidence interval

220 ng was associated with reduced readmissions (incidence rate ratio [IRR]: 0.56; 95% confidence interva

221 The incidence rate ratio comparing SMC within the past 28 da

222 After adjustment for age at follow-up, the incidence rate ratio for the comparison of the vaccinate

223 ve an HR of 0.56 (0.34-0.91; p=0.019) and an incidence rate ratio of 0.50 (0.31-0.82; p=0.0057).

224 account for multiple primary events gave an incidence rate ratio of 0.58 (0.39-0.87; p=0.0085).

225 an 4.28% was associated with an exacerbation incidence rate ratio of 2.5 (95% CI = 1.3-4.7) versus a

226 act appeared even stronger, with an adjusted incidence rate ratio of 3.6 (95% CI 1.8-7.4).

227 interval analysis was used to calculate the incidence rate ratio of bursitis in a risk interval of 0

228 Improvements in QoL and the incidence rate ratio of URTI (0.60, p < 0.0001) were rec

229 After adjustment for all covariates, the incidence rate ratio was 0.12 (95% CI, 0.00 to 0.34) amo

230 itional adjustment for other covariates, the incidence rate ratio was 0.37 (95% CI, 0.21 to 0.57).

231 kers were asymptomatic when tested (adjusted incidence rate ratio, 0.11; 95% confidence interval, 0.0

232 95% CI, 0.20 to 0.43), and hospitalizations (incidence rate ratio, 0.21; 95% CI, 0.13 to 0.34).

233 d cases as compared with 253 expected cases; incidence rate ratio, 0.25; 95% confidence interval [CI]

234 cases of acute chest syndrome or pneumonia (incidence rate ratio, 0.27; 95% CI, 0.11 to 0.56), trans

235 , 0.27; 95% CI, 0.11 to 0.56), transfusions (incidence rate ratio, 0.30; 95% CI, 0.20 to 0.43), and h

236 , 0.34 to 0.54), vaso-occlusive pain crises (incidence rate ratio, 0.43; 95% CI, 0.34 to 0.56), cases

237 ad fewer sickle cell-related adverse events (incidence rate ratio, 0.43; 95% confidence interval [CI]

238 eart failure admissions declined after TAVR (incidence rate ratio, 0.55 [95% CI, 0.48-0.62], P<0.001)

239 0.55 [95% CI, 0.48-0.62], P<0.001) and SAVR (incidence rate ratio, 0.76 [95% CI, 0.65-0.88], P<0.001)

240 recurrent) of AF/AFL events (337 versus 432; incidence rate ratio, 0.77 [95% CI, 0.64-0.92]; P=0.005)

241 r was 36.1 versus 41.5 per 100 person-years (incidence rate ratio, 0.87 [CI, 0.65 to 1.15]).

242 with significant changes in length of stay (incidence rate ratio, 1.02; 95% confidence interval, .97

243 , 0.9 days [95% CI, -3.25 to 5.05]; adjusted incidence rate ratio, 1.13 [95% CI, 0.79 to 1.63]; P = .

244 CI, 1.28-1.38), and C. difficile infection (incidence rate ratio, 1.18; 95% CI, 1.07-1.31).

245 n in the control group (mean 0.71 +/- 1.20) (incidence rate ratio, 1.46; 95% CI, 1.15-1.86).

246 her rates of cardiovascular hospitalization (incidence rate ratio, 1.78; P=0.012) but similar annual

247 [CI], 1.6-2.8), the rate of hospitalization (incidence rate ratio, 2.8; 95% CI, 1.9-4.1), and the cas

248 end toward fewer episodes of severe malaria (incidence rate ratio: 0.39; 95% CI: 0.14, 1.12).

249 e of intervention than the comparison areas (incidence rate ratio: 0.536 [0.337-0.852]); however, inc

250 ant reduction in PPCI as compared with 2019 (incidence rate ratio: 0.811; 95% confidence interval: 0.

251 e transplanted 16% less frequently (adjusted incidence rate ratio: 0.84, 95% CI: 0.73-0.98, P = 0.02)

252 % CI: 0.46 to 1.57) or hospitalization time (incidence rate ratio: 1.17; 95% CI: 0.93 to 1.46).

253 The incidence-rate ratio was 0.64 (95% CI, 0.42 to 0.98) in

254 Incidence rate ratios (IRRs) and absolute risk differenc

255 Incidence rate ratios (IRRs) comparing antibiotic use in

256 of immunocompromising condition and provided incidence rate ratios (IRRs) comparing to immunocompeten

257 d human immunodeficiency virus incidence and incidence rate ratios (IRRs) for black and Hispanic vs w

258 We found elevated incidence rate ratios (IRRs) for many immune-related con

259 Incidence rate ratios (IRRs) were compared for units rec

260 Incidence rate ratios (IRRs) were derived by comparing i

261 Using Poisson regression, we estimated incidence rate ratios (IRRs) with 95% confidence interva

262 Incidence rate ratios (IRRs) with 95% confidence interva

263 -2011 to 2016) periods was used to calculate incidence rate ratios (IRRs).

264 ality rate ratios (MRRs) and hospitalization incidence rate ratios (IRRs).

265 We estimated incidence rate ratios (RRs) and 95% confidence intervals

266 f taxed beverages decreased by 27% (ratio of incidence rate ratios [RIRR], 0.73 [95% CI, 0.70 to 0.75

267 dence between non-White groups and NHW using incidence rate ratios and 95% confidence intervals (CIs)

268 d risk among HPV vaccine-exposed girls, with incidence rate ratios close to 1.0 for abdominal pain, n

269 Incidence rate ratios comparing post-IRS to pre-IRS inci

270 ions annual incidences from 2004 to 2017 and incidence rate ratios comparing the PCV13 (2014-2017) wi

271 el tests and Poisson regressions to estimate incidence rate ratios for new leprosy case detection and

272 Incidence rate ratios of PD associated with use of beta2

273 The incidence rate ratios showed similar patterns.

274 Incidence rate ratios were calculated to count all outco

275 Rates and incidence rate ratios were estimated using Poisson regre

276 ase-series method, we estimated age-adjusted incidence rate ratios within 1-7, 8-21, and 1-21 days of

277 ed with 79% increased risk for incident CKD (incidence rate ratios, 1.79; 95% confidence interval, 1.

278 on were significantly associated with higher incidence rate ratios.

279 Incidence rate, relative rate (RR), and vaccine effectiv

280 .8)] had highest and lowest age-standardised incidence rates, respectively.

281 ries are needed to more precisely define the incidence rates, risk factors, primary and secondary mod

282 California's diagnosed autism incidence rate rose from 0.49 per 1,000 3-6 y olds in 19

283 Incidence rates showed a decline following the implement

284 the two groups stratified for WHO grades as: incidence rates, survival probabilities and cumulative r

285 study was to provide detailed information on incidence rates, types of microorganisms, and outcomes o

286 e coronavirus 2 (SARS-CoV-2) infection, with incidence rates varying from 8 to 33% depending on the s

287 nge 16-1160) and the overall HCV reinfection incidence rate was 1.89 per 100 person-years (py; 95% co

288 The incidence rate was 144 episodes (95% confidence interval

289 The ADHD incidence rate was 3.41 per 1,000 person-years in the Td

290 0 person-years (PYs) (95% CI 5.2-9.2) and TB incidence rate was 5.4/100 PYs (95% CI 3.9-7.5).

291 HZ incidence rate was 9.92/1000 person-years (95% confidenc

292 The incidence rate was calculated, and 95% confidence interv

293 The gout incidence rate was lower among patients prescribed an SG

294 Ten-, 20-, and 30-year HE incidence rates were 13%, 24%, and 28%, respectively.

295 Unstandardized and standardized incidence rates were calculated by year, 10-year age gro

296 Chlamydia and gonorrhea incidence rates were calculated each year by demographic

297 age-specific and age-adjusted salmonellosis incidence rates were calculated for each census tract po

298 In all age groups, pregnancy incidence rates were highest in women who had started AR

299 The lowest prescription incidence rates were in London, and the highest were in

300 When stratified by age, the highest incidence rates were registered at age 60-69 years.